Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Jan Nilsson

Professor

Default user image.

Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages

Author

  • Ngoc Nguyen Lunde
  • Ida Gregersen
  • Thor Ueland
  • Christian Shetelig
  • Sverre Holm
  • Xiang Yi Kong
  • Annika E. Michelsen
  • Kari Otterdal
  • Arne Yndestad
  • Kaspar Broch
  • Lars Gullestad
  • Tuula A. Nyman
  • Bjørn Bendz
  • Jan Eritsland
  • Pavel Hoffmann
  • Karolina Skagen
  • Isabel Gonçalves
  • Jan Nilsson
  • Magnus Grenegård
  • Marcin Poreba
  • Marcin Drag
  • Ingebjørg Seljeflot
  • Bjørnar Sporsheim
  • Terje Espevik
  • Mona Skjelland
  • Harald Thidemann Johansen
  • Rigmor Solberg
  • Pål Aukrust
  • Harry Björkbacka
  • Geir Øystein Andersen
  • Bente Halvorsen

Summary, in English

Background and aims: We have previously found increased levels of the cysteine protease legumain in plasma and plaques from patients with carotid atherosclerosis. This study further investigated legumain during acute cardiovascular events. Methods: Circulating levels of legumain from patients and legumain released from platelets were assessed by enzyme-linked-immunosorbent assay. Quantitative PCR and immunoblotting were used to study expression, while localization was visualized by immunohistochemistry. Results: In the SUMMIT Malmö cohort (n = 339 with or without type 2 diabetes and/or cardiovascular disease [CVD], and 64 healthy controls), the levels of circulating legumain were associated with the presence of CVD in non-diabetics, with no relation to outcome. In symptomatic carotid plaques and in samples from both coronary and intracerebral thrombi obtained during acute cardiovascular events, legumain was co-localized with macrophages in the same regions as platelets. In vitro, legumain was shown to be present in and released from platelets upon activation. In addition, THP-1 macrophages exposed to releasate from activated platelets showed increased legumain expression. Interestingly, primary peripheral blood mononuclear cells stimulated with recombinant legumain promoted anti-inflammatory responses. Finally, in a STEMI population (POSTEMI; n = 272), patients had significantly higher circulating legumain before and immediately after percutaneous coronary intervention compared with healthy controls (n = 67), and high levels were associated with improved outcome. Conclusions: Our data demonstrate for the first time that legumain is upregulated during acute cardiovascular events and is associated with improved outcome.

Department/s

  • EXODIAB: Excellence in Diabetes Research in Sweden
  • Cardiovascular Research - Translational Studies
  • Cardiovascular Research - Immunity and Atherosclerosis
  • EpiHealth: Epidemiology for Health
  • Cardiovascular Research - Cellular Metabolism and Inflammation

Publishing year

2020-03-01

Language

English

Pages

74-82

Publication/Series

Atherosclerosis

Volume

296

Document type

Journal article

Publisher

Elsevier

Topic

  • Cardiac and Cardiovascular Systems

Keywords

  • Cardiovascular disease
  • Legumain
  • Macrophage
  • Plaque modification
  • Platelets
  • Protease

Status

Published

Research group

  • Cardiovascular Research - Translational Studies
  • Cardiovascular Research - Immunity and Atherosclerosis
  • Cardiovascular Research - Cellular Metabolism and Inflammation

ISBN/ISSN/Other

  • ISSN: 0021-9150